5TX6

Structure of TGF-beta2 derivative with deletion of residues 52-71 and 10 single amino acid mutations (mmTGF-beta2-7M)

  • Classification: CYTOKINE
  • Organism(s): Mus musculus
  • Expression System: Escherichia coli
  • Mutation(s): 10 

  • Deposited: 2016-11-15 Released: 2017-03-01 
  • Deposition Author(s): Petrunak, E.M., Hinck, A.P.
  • Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences; National Institutes of Health/National Cancer Institute; Robert A. Welch Foundation 

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.746 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.213 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

An engineered transforming growth factor beta (TGF-beta ) monomer that functions as a dominant negative to block TGF-beta signaling.

Kim, S.K.Barron, L.Hinck, C.S.Petrunak, E.M.Cano, K.E.Thangirala, A.Iskra, B.Brothers, M.Vonberg, M.Leal, B.Richter, B.Kodali, R.Taylor, A.B.Du, S.Barnes, C.O.Sulea, T.Calero, G.Hart, P.J.Hart, M.J.Demeler, B.Hinck, A.P.

(2017) J. Biol. Chem. 292: 7173-7188

  • DOI: 10.1074/jbc.M116.768754
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The transforming growth factor β isoforms, TGF-β1, -β2, and -β3, are small secreted homodimeric signaling proteins with essential roles in regulating the adaptive immune system and maintaining the extracellular matrix. However, dysregulation of the T ...

    The transforming growth factor β isoforms, TGF-β1, -β2, and -β3, are small secreted homodimeric signaling proteins with essential roles in regulating the adaptive immune system and maintaining the extracellular matrix. However, dysregulation of the TGF-β pathway is responsible for promoting the progression of several human diseases, including cancer and fibrosis. Despite the known importance of TGF-βs in promoting disease progression, no inhibitors have been approved for use in humans. Herein, we describe an engineered TGF-β monomer, lacking the heel helix, a structural motif essential for binding the TGF-β type I receptor (TβRI) but dispensable for binding the other receptor required for TGF-β signaling, the TGF-β type II receptor (TβRII), as an alternative therapeutic modality for blocking TGF-β signaling in humans. As shown through binding studies and crystallography, the engineered monomer retained the same overall structure of native TGF-β monomers and bound TβRII in an identical manner. Cell-based luciferase assays showed that the engineered monomer functioned as a dominant negative to inhibit TGF-β signaling with a Ki of 20-70 nm Investigation of the mechanism showed that the high affinity of the engineered monomer for TβRII, coupled with its reduced ability to non-covalently dimerize and its inability to bind and recruit TβRI, enabled it to bind endogenous TβRII but prevented it from binding and recruiting TβRI to form a signaling complex. Such engineered monomers provide a new avenue to probe and manipulate TGF-β signaling and may inform similar modifications of other TGF-β family members.


    Organizational Affiliation

    the Departments of Biochemistry and Structural Biology and.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Transforming growth factor beta-2
B, A, C
93Mus musculusMutation(s): 10 
Gene Names: Tgfb2
Find proteins for P27090 (Mus musculus)
Go to UniProtKB:  P27090
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
CA
Query on CA

Download SDF File 
Download CCD File 
A
CALCIUM ION
Ca
BHPQYMZQTOCNFJ-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.746 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.213 
  • Space Group: P 31 2 1
Unit Cell:
Length (Å)Angle (°)
a = 81.744α = 90.00
b = 81.744β = 90.00
c = 80.926γ = 120.00
Software Package:
Software NamePurpose
PHENIXrefinement
iMOSFLMdata reduction
SCALAdata scaling
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical SciencesUnited StatesGM58670
National Institutes of Health/National Cancer InstituteUnited StatesCA172886
Robert A. Welch FoundationUnited StatesAQ1842

Revision History 

  • Version 1.0: 2017-03-01
    Type: Initial release
  • Version 1.1: 2017-03-08
    Type: Database references
  • Version 1.2: 2017-05-10
    Type: Database references
  • Version 1.3: 2017-09-27
    Type: Author supporting evidence